Cardiovascular pharmacology of 5-hydroxytryptamine prospective therapeutic applications ; [international symposium held in Amsterdam

Edited By P.r. Saxena ... [et Al.]. Based On An International Symposium Held In Amsterdam In 1989 Under The Auspices Of The Serotonin Club, The Dutch Pharmacological Society, And The Erasmus University Rotterdam. Includes Index. Includes Bibliographical References. Front Matter ....Pages i-xxv Front Matter ....Pages 1-1 The distribution and biochemistry of 5-hydroxytryptamine in the cardiovascular system (Tony J. Verbeuren)....Pages 3-13 5-Hydroxytryptamine transport systems (David Graham, Salomon Z. Langer)....Pages 15-30 Cloning of the choroid plexus 5-HT1C receptor (Paul R. Hartig)....Pages 31-39 Regional differences in the transduction mechanisms of 5-hydroxytryptamine receptors in the mammalian brain (M. Hamon, M. B. Emerit, S. el Mestikawy, M. C. Gallissot, H. Gozlan)....Pages 41-59 Reduction of a distinct pool of monoamines by ketanserin in peripheral tissues (J. E. Leysen, J. Wynants, A. Eens, P. A. J. Janssen)....Pages 61-66 Front Matter ....Pages 67-67 Putative agonists and antagonists at 5-HT1-like receptors (Wasyl Feniuk, Patrick P. A. Humphrey)....Pages 69-80 Agonists and antagonists of 5-HT2 receptors (E. J. Mylecharane)....Pages 81-100 Agonists and antagonists of 5-HT3 receptors (John R. Fozard)....Pages 101-115 The continuing story of 5-hydroxytryptamine receptors: a 5-HT3 receptor modulates dopamine release from rat striatal slice (Patrizio Blandina, Joseph Goldfarb, Jack Peter Green)....Pages 117-126 Allosteric modulation of arterial 5-HT2 receptors (A. J. Kaumann, A. M. Brown)....Pages 127-142 An analysis of unsurmountable antagonism to 5-hydroxytryptamine in the isolated perfused rat kidney: evidence for pseudoirreversible inhibition (D. A. Craig, A. G. Ornstein, D. E. Clarke)....Pages 143-155 Tryptamine fingerprints in the classification of 5-hydroxytryptamine receptors (G. R. Martin, P. Leff, S. J. Maclennan)....Pages 157-162 Front Matter ....Pages 163-163 Central neuronal responses and 5-hydroxytryptamine receptors (M. H. T. Roberts, M. Davies)....Pages 165-176 5-Hydroxytryptamine and related drugs and autonomic ganglia (D. I. Wallis, P. Elliott)....Pages 177-190 5-Hydroxytryptaminergic neurotransmission in the gut (Michael D. Gershon, Gary M. Mawe, Theresa A. Branchek)....Pages 191-210 Presence of 5-hydroxytryptamine in adrenergic nerves of the brain circulation: its role in sympathetic neurotransmission and regulation of the cerebral vessel wall (Christer Owman, Jing-Yu Chang, Jan Erik Hardebo)....Pages 211-230 Front Matter ....Pages 231-231 Cardiovascular reflexes and 5-hydroxytryptamine (Daniel S. McQueen)....Pages 233-245 Central 5-hydroxytryptamine (5-HT) and its effect on the cardiovascular system (A. K. Mir, J. R. Fozard)....Pages 247-258 The central antihypertensive action of 5-hydroxytryptamine: The location of site of action (J. H. Coote)....Pages 259-270 The role of 5-hydroxytryptamine in the regulation of sympathetic nerve discharge (Robert B. McCall)....Pages 271-283 5-Hydroxytryptamine and related drugs and transmitter release from autonomic nerves in the cardiovascular system (M. Göthert, K. Fink, G. Molderings, E. Schlicker)....Pages 285-294 Receptors for 5-hydroxytryptamine in the cardiovascular system (Marlene L. Cohen)....Pages 295-302 Altered responses to 5-hydroxytryptamine in hypertension and other cardiovascular disorders (J. M. Van Nueten, W. J. Janssens, P. A. J. Janssen)....Pages 303-310 5-Hydroxytryptamine receptor antagonists as antihypertensive drugs (Pramod R. Saxena)....Pages 311-318 Ketanserin in hypertension and vasospastic disease: mechanism of action (Maarten A. D. H. Schalekamp, Gert-Jan Wenting)....Pages 319-327 Renin secretion and 5-hydroxytryptamine (William F. Ganong)....Pages 329-337 Acute and long-term effects of 5-hydroxytryptamine in isolated renal arteries in vitro (J. G. R. de Mey, M. P. Uitendaal, H. C. M. Boonen, M. J. J. F. Vrijdag)....Pages 339-342 Ventrolateral medullary pressor area: site of hypotensive and sympatho-inhibitory effects of (±) 8-OH-DPAT in anaesthetized dogs (Michel Laubie, Madeleine Drouillat, Hubert Dabiré, Claudie Cherqui, Henri Schmitt)....Pages 343-346 Evidence that spiperone reverses the additional sympathoinhibitory action of urapidil in anaesthetised, prazosin-pretreated cats (Andrew G. Ramage)....Pages 347-350 The effects of intrathecal ketanserin and phentolamine on heart rate and arterial blood pressure in the rat (K. Mohan Dhasmana, Ajay K. Banerjee, Pramod R. Saxena)....Pages 351-354 Early clinical experience with flesinoxan, a new selective 5-HT1A receptor agonist (J. M. de Voogd, G. Prager)....Pages 355-359 Front Matter ....Pages 361-361 Coronary circulation and 5-hydroxytryptamine (James A. Angus, Archer Broughton, Thomas M. Cocks, Christine E. Wright)....Pages 365-378 The endothelium and the role of 5-hydroxytryptamine in vascular disease (Paul M. Vanhoutte)....Pages 379-389 Vascular pharmacology of 5-hydroxytryptamine in humans (Gerald J. Blauw, Peter Van Brummelen, Pieter A. Van Zwieten)....Pages 391-399 Ketanserin in the treatment of septic shock (Arend J. J. Woittiez, Jot Wolthuis, Leo Van Bergeijk)....Pages 401-404 Front Matter ....Pages 405-405 5-Hydroxytryptamine and migraine (Pramod R. Saxena)....Pages 407-416 A rational approach to identifying a fundamentally new drug for the treatment of migraine (P. P. A. Humphrey, E. Apperley, W. Feniuk, M. J. Perren)....Pages 417-431 Treatment of migraine with drugs related to 5-hydroxytryptamine (P. Tfelt-Hansen, T. H. Nielsen)....Pages 433-441 Front Matter ....Pages 443-443 The human platelet 5-HT2-receptor: an up-date (D. de Chaffoy de Courcelles, F. de Clerck)....Pages 445-457 ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and ex vivo (Thomas P. Blackburn, Stephen J. Haworth, Carol L. Jessup, Pamela B. Morton, Christine Williams)....Pages 459-463 Back Matter ....Pages 465-471